STOCK TITAN

InspireMD, Inc. - NSPR STOCK NEWS

Welcome to our dedicated page for InspireMD news (Ticker: NSPR), a resource for investors and traders seeking the latest updates and insights on InspireMD stock.

InspireMD, Inc. (NASDAQ: NSPR), located at 800 Boylston Street, Suite 16041, Boston, Massachusetts, is a pioneering medical device company. It specializes in the development and commercialization of its proprietary MicroNet stent platform technology, which addresses complex vascular and coronary diseases. The company's flagship products include the CGuard Carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS).

The CGuard EPS, which integrates MicroNet technology with a self-expandable nitinol stent, is primarily used for carotid artery applications and is a significant revenue driver for the company. InspireMD operates globally, with key markets in Italy, Germany, Russia, among others.

In a recent move, InspireMD has focused on expanding its intellectual property portfolio to support its strategic direction. October 2023 saw the Centers for Medicare and Medicaid Services (CMS) expand coverage for carotid artery stenting, including asymptomatic and standard-risk patients. This development is expected to enhance the adoption of InspireMD's products.

Additionally, in the third quarter of 2023, InspireMD reported its financial results and ongoing projects. They are currently enrolling patients in a study to investigate the safety and feasibility of using CGuard EPS for treating acute ischemic stroke patients with tandem lesions. This study is expected to enroll 15 patients across three U.S. sites.

CEO Marvin Slosman emphasized the importance of this study in addressing carotid lesions in acute stroke settings, marking a crucial step in their long-term growth strategy. The company also continues its work on the Premarket Approval Application (PMA) for the C-GUARDIANS U.S. IDE trial, anticipating key milestones in 2024 and 2025.

InspireMD's common stock is listed on the Nasdaq under the ticker symbol NSPR. For more information, visit their website at www.inspiremd.com.

Rhea-AI Summary
InspireMD announces senior leadership additions and changes to support commercial growth initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
InspireMD to present 30-day results from C-Guardians trial at VIVA23 conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.01%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.41%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.7%
Tags
-
Rhea-AI Summary
InspireMD secures $42.2 million financing upfront with potential for additional $71.4 million tied to milestones
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.9%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.9%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags

FAQ

What is the current stock price of InspireMD (NSPR)?

The current stock price of InspireMD (NSPR) is $3 as of December 20, 2024.

What is the market cap of InspireMD (NSPR)?

The market cap of InspireMD (NSPR) is approximately 75.1M.

What does InspireMD, Inc. specialize in?

InspireMD specializes in the development and commercialization of proprietary MicroNet stent platform technology for vascular and coronary diseases.

What are the key products of InspireMD?

The key products are CGuard Carotid Embolic Prevention System (CGuard EPS) and MGuard Prime Embolic Protection System (MGuard Prime EPS).

Where is InspireMD headquartered?

InspireMD is headquartered at 800 Boylston Street, Suite 16041, Boston, Massachusetts, United States.

In which markets does InspireMD operate?

InspireMD operates in multiple countries, including Italy, Germany, and Russia.

What recent developments have been announced by InspireMD?

Recent developments include the expansion of CMS coverage for carotid artery stenting and ongoing studies for acute ischemic stroke treatment.

Who is the CEO of InspireMD?

The CEO of InspireMD is Marvin Slosman.

What are the financial results for InspireMD in the third quarter of 2023?

The detailed financial results for the third quarter of 2023 can be found in the company's report on Form 10-Q filed with the SEC.

What is the trading symbol for InspireMD?

InspireMD's common stock is quoted on Nasdaq under the ticker symbol NSPR.

What is the MicroNet technology?

MicroNet is a proprietary technology used in InspireMD's stent systems designed to provide superior embolic protection and enhance patient outcomes.

How can I get more information about InspireMD?

For more information, you can visit InspireMD's official website at www.inspiremd.com.

InspireMD, Inc.

Nasdaq:NSPR

NSPR Rankings

NSPR Stock Data

75.12M
19.52M
16.99%
40.85%
0.76%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
MIAMI